Yesterday the wording was released for the black box or warning label on the asthma drug Xolair by Genentech Inc. The medication, generically known as omalizumab, is given by injection and was developed for individuals ages 12 and above who have moderate to severe allergic asthma and have not responded to inhaled steroids.
The FDA mandated the revised label because patients receiving Xolair can experience anaphylaxis, which is a life-threatening reaction characterized by shortness of breath,...
